Delsite and Nastech Sign Pact to Enhance Intranasal Delivery
DelSite Biotechnologies, Inc. (Irving, TX, www.delsite.com), a wholly-owned subsidiary of Carrington Laboratories, Inc. (Irving, TX, www.carringtonlabs.com), has entered into a non-exclusive technology evaluation agreement with Nastech Pharmaceutical Company, Inc. (Bothell, DC, www.nastech.com), for the purpose of evaluating DelSite's GelSite polymer for enhancing the intranasal delivery of peptide and protein therapeutics.
DelSite Biotechnologies, Inc. (Irving, TX, www.delsite.com), a wholly-owned subsidiary of Carrington Laboratories, Inc. (Irving, TX, www.carringtonlabs.com), has entered into a non-exclusive technology evaluation agreement with Nastech Pharmaceutical Company, Inc. (Bothell, DC, www.nastech.com), for the purpose of evaluating DelSite's GelSite polymer for enhancing the intranasal delivery of peptide and protein therapeutics. Financial terms of the agreement were not disclosed.
GelSite polymer is a novel, naturally occurring, mucoadhesive ionic carbohydrate polymer capable of forming a gel when brought into contact with nasal fluids. Gelling occurs with liquid as well as powder formulations and provides sustained release and prolonged nasal residence time that may enhance the nasal delivery of therapeutics or vaccines.
DelSite has evaluated GelSite polymer for delivery of various protein and peptide therapeutics and vaccine antigens and has completed a series of toxicology studies on this polymer. A drug master file (DMF) for use of GelSite polymer in mucosal applications was filed in 2005 and was recently updated with both CBER and CDER.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
